Trials / Completed
CompletedNCT01072331
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
Pharmacokinetic/Pharmacodynamic Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of MP-513 on 24-h glycemic control in patients with type 2 Diabetes for 4 weeks administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-513 | MP-513 10 mg, once a day, for 4 weeks |
| DRUG | MP-513 | MP-513 20 mg, once a day, for 4 weeks |
| DRUG | Placebo of MP-513 | MP-513 placebo, once a day, for 4 weeks |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2010-02-22
- Last updated
- 2026-01-02
- Results posted
- 2012-12-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01072331. Inclusion in this directory is not an endorsement.